JP6849007B2 - 造粒組成物、及びその製造方法 - Google Patents

造粒組成物、及びその製造方法 Download PDF

Info

Publication number
JP6849007B2
JP6849007B2 JP2019071948A JP2019071948A JP6849007B2 JP 6849007 B2 JP6849007 B2 JP 6849007B2 JP 2019071948 A JP2019071948 A JP 2019071948A JP 2019071948 A JP2019071948 A JP 2019071948A JP 6849007 B2 JP6849007 B2 JP 6849007B2
Authority
JP
Japan
Prior art keywords
particles
binder
granulated
granulation
nuclear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019071948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019182856A (ja
Inventor
俊介 清
俊介 清
三寿々 峯田
三寿々 峯田
主税 森実
主税 森実
亙 平澤
亙 平澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunsho Pharmaceutical Co Ltd
Original Assignee
Sunsho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunsho Pharmaceutical Co Ltd filed Critical Sunsho Pharmaceutical Co Ltd
Publication of JP2019182856A publication Critical patent/JP2019182856A/ja
Priority to JP2020208264A priority Critical patent/JP7319956B2/ja
Application granted granted Critical
Publication of JP6849007B2 publication Critical patent/JP6849007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019071948A 2018-04-12 2019-04-04 造粒組成物、及びその製造方法 Active JP6849007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020208264A JP7319956B2 (ja) 2018-04-12 2020-12-16 造粒組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018076957 2018-04-12
JP2018076957 2018-04-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020208264A Division JP7319956B2 (ja) 2018-04-12 2020-12-16 造粒組成物

Publications (2)

Publication Number Publication Date
JP2019182856A JP2019182856A (ja) 2019-10-24
JP6849007B2 true JP6849007B2 (ja) 2021-03-24

Family

ID=68164126

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019071948A Active JP6849007B2 (ja) 2018-04-12 2019-04-04 造粒組成物、及びその製造方法
JP2020208264A Active JP7319956B2 (ja) 2018-04-12 2020-12-16 造粒組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020208264A Active JP7319956B2 (ja) 2018-04-12 2020-12-16 造粒組成物

Country Status (3)

Country Link
US (1) US12496277B2 (enExample)
JP (2) JP6849007B2 (enExample)
WO (1) WO2019198612A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7555333B2 (ja) * 2019-04-15 2024-09-24 三生医薬株式会社 錠剤及び錠剤の製造方法
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
JPWO2025037595A1 (enExample) * 2023-08-14 2025-02-20

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63188621A (ja) 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
JPH05309314A (ja) 1992-05-07 1993-11-22 Sumitomo Pharmaceut Co Ltd コーティング方法
JP2987813B2 (ja) 1993-07-12 1999-12-06 住友製薬株式会社 ワックス被覆製剤およびその製法
JP3412899B2 (ja) 1994-03-17 2003-06-03 共和薬品工業株式会社 徐放性細粒剤およびその製造方法
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
JP4974419B2 (ja) 2001-06-12 2012-07-11 東和薬品株式会社 薬物含有徐放性顆粒およびそれを含む錠剤
JP4833464B2 (ja) 2001-11-28 2011-12-07 大正製薬株式会社 難溶性薬物含有固形製剤の製造方法
JP2003292437A (ja) 2002-01-31 2003-10-15 Sumitomo Chem Co Ltd 脂溶性ビタミン及び／またはカロチノイド含有粒状体の製造方法
JP4684545B2 (ja) 2002-09-26 2011-05-18 大日本住友製薬株式会社 溶出性の良好なイソキサゾール誘導体経口製剤
JP2004250367A (ja) 2003-02-19 2004-09-09 Sumitomo Chem Co Ltd 親油性化合物を含有する粒子の製造方法および製造装置
JP4578124B2 (ja) 2003-03-12 2010-11-10 武田薬品工業株式会社 高濃度に活性成分を球形核に付着させた医薬組成物
JP4065902B2 (ja) * 2006-04-28 2008-03-26 ライオン株式会社 造粒粒子、錠剤、及び造粒粒子の製造方法
WO2007135470A1 (en) 2006-05-19 2007-11-29 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Process for the preparation and surface coating of pellets
WO2009048073A1 (ja) 2007-10-09 2009-04-16 Takeda Pharmaceutical Company Limited 顆粒の被覆方法
JP2009107944A (ja) 2007-10-26 2009-05-21 Takeda Chem Ind Ltd 医薬組成物
JP2012001460A (ja) 2010-06-15 2012-01-05 Ohara Yakuhin Kogyo Kk 光過敏性薬物の安定化法
JP2013011026A (ja) 2011-06-28 2013-01-17 Daicel Corp セルロースナノファイバーを主成分とする高強度材料及びその製造方法
JP6138635B2 (ja) 2013-08-30 2017-05-31 旭化成株式会社 セルロース系核粒子及びその製造方法
JP6700084B2 (ja) 2016-03-30 2020-05-27 株式会社ファンケル コーティング顆粒
JP2022188621A (ja) 2021-06-09 2022-12-21 パナソニックＩｐマネジメント株式会社 設定システム、蓄電制御システム、蓄電池システム、設定方法、及びプログラム

Also Published As

Publication number Publication date
JP2021042251A (ja) 2021-03-18
JP7319956B2 (ja) 2023-08-02
US12496277B2 (en) 2025-12-16
WO2019198612A1 (ja) 2019-10-17
US20210161820A1 (en) 2021-06-03
JP2019182856A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
JP6932746B2 (ja) エンザルタミドの製剤
JP5461179B2 (ja) セルロース系微小核粒子及びその製造方法
ES2406939T3 (es) Preparación farmacéutica de matriz sólida
US20160120809A1 (en) Orally disintegrating tablet formulation for enhanced bioavailability
JP2010090146A (ja) 薬効を有する医薬の含有割合が高いメサラジンサッシェ
CN100404071C (zh) 医药用组合物
HK1209337A1 (en) Medicament-containing hollow particle
JP2021042251A (ja) 造粒組成物
JP2008214334A (ja) 被覆された薬物含有粒子および該粒子を含む固形製剤
JP2024128041A (ja) 錠剤及び錠剤の製造方法
JP3833314B2 (ja) 発泡性組成物およびその製造方法
N Politis et al. Pelletization processes for pharmaceutical applications: a patent review
JP4716063B2 (ja) 不快味マスキング粒子及びこれを含有する経口製剤
JP7147523B2 (ja) 造粒方法
WO2014017507A1 (ja) 固形製剤
WO2022072099A9 (en) Immediate release dosage forms, methods of making and using
JP6211044B2 (ja) 薬物含有中空粒子
CN115212173B (zh) 一种盐酸氨溴索球形缓释微粒、制备方法及用途
TWI597063B (zh) 藥物組成物及其製備方法
Patel Formulation and evaluation of gastroretentive floating pellets of nizatidine
CN113164455B (zh) 难溶性药物的固体分散体
Pai et al. Multiple Unit Particle System (MUPS): Novel technology for preparation of Extended Release (ER) tablets
JP5841257B2 (ja) 薬物含有中空粒子
HK40008438A (en) Medicament-containing hollow particle
HK40008441A (en) Medicament-containing hollow particle

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210215

R150 Certificate of patent or registration of utility model

Ref document number: 6849007

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250